Ophthalmic solution
Disclosed herein an ophthalmic formulation comprises carbonic anhydrase inhibitor(s) alone, in an aqueous solution or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents and a manufacturing process thereof. The present invention further relates to the composition(s) manufactured by the process described herein and methods for treating persons suffering from glaucoma or ocular hypertension. In particular, the persons are treated with carbonic anhydrase inhibitor(s) alone or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents to control their intraocular pressure (IOP). Further disclosed herein the formulations as manufactured relate to a highly solubilized form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.
1. An aqueous sterile, ophthalmic pharmaceutical formulation, comprising:
(A) brinzolamide, or a pharmaceutically acceptable salt thereof, as an active agent in an amount of from 0.3-0.5 w/w % of the formulation,
(B) polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, in an amount of from 0.4-0.8 w/w % of the formulation,
(C) polysorbate 80, in an amount of 1.0 w/w % of the formulation;
(D) an additional therapeutically active agent, which is latanoprost, wherein the latanoprost is present in an amount of 0.005 w/w % of the formulation;
(E) edetate disodium, in an amount of 0.01 w/w % of the formulation;
(F) mannitol, in an amount of 3.3 w/w % of the formulation;
(G) carbomer, in an amount of 0.4-0.45 w/w % of the formulation; and
(H) sodium chloride, in an amount of 0.19 w/w % of the formulation;
wherein the formulation is a solution and the formulation pH is from 5.5 to 8.
2. The formulation of claim 1 , wherein the solution is in the form of drops.
3. An aqueous sterile, ophthalmic pharmaceutical formulation, comprising:
(A) brinzolamide, or a pharmaceutically acceptable salt thereof, as an active agent in an amount of 0.5 w/w % of the formulation,
(B) polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, in an amount of 0.8 w/w % of the formulation,
(C) polysorbate 80, in an amount of 1.0 w/w % of the formulation;
(D) an additional therapeutically active agent, which is timolol, wherein the timolol is present in an amount of 0.5 w/w % of the formulation;
(E) edetate disodium, in an amount of 0.01 w/w % of the formulation;
(F) mannitol, in an amount of 3 w/w % of the formulation;
(G) carbomer, in an amount of 0.42 w/w % of the formulation; and
(H) sodium chloride, in an amount of 0.1 w/w % of the formulation;
wherein the formulation is a solution and the formulation pH is from 5.5 to 8.
4. An aqueous sterile, ophthalmic pharmaceutical formulation, comprising:
(A) brinzolamide, or a pharmaceutically acceptable salt thereof, as an active agent in an amount of 0.5 w/w % of the formulation,
(B) polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, in an amount of 0.8 w/w % of the formulation,
(C) polysorbate 80, in an amount of 1.0 w/w % of the formulation;
(D) an additional therapeutically active agent, which is timolol, wherein the timolol is present in an amount of 0.5 w/w % of the formulation;
(E) edetate disodium, in an amount of 0.01 w/w % of the formulation;
(F) mannitol, in an amount of 2.5 w/w % of the formulation;
(G) carbomer, in an amount of 0.42 w/w % of the formulation;
(H) boric acid, in an amount of 0.19 w/w % of the formulation;
(I) sodium borate, in an amount of 0.01 w/w % of the formulation;
(J) zinc chloride, in an amount of 0.10 w/w % of the formulation;
(K) sodium metabisulphate, in an amount of 0.2 w/w % of the formulation; and
wherein the formulation is a solution and the formulation pH is from 5.5 to 8.
5. The formulation of claim 3 , wherein the solution is in the form of drops.
6. The formulation of claim 4 , wherein the solution is in the form of drops.
7. A method of treating elevated intraocular pressure in a patient with glaucoma or ocular hypertension, the method comprising administering to the patient the ophthalmic formulation of claim 1 .
8. The method of claim 7 , wherein the formulation is administered once a day, twice a day, or three times a day to each eye in need thereof.
9. A method of treating elevated intraocular pressure in a patient with glaucoma or ocular hypertension, the method comprising administering to the patient the ophthalmic formulation of claim 3 .
10. The method of claim 9 , wherein the formulation is administered once a day, twice a day, or three times a day to each eye in need thereof.
11. A method of treating elevated intraocular pressure in a patient with glaucoma or ocular hypertension, the method comprising administering to the patient the ophthalmic formulation of claim 4 .
12. The method of claim 11 , wherein the formulation is administered once a day, twice a day, or three times a day to each eye in need thereof.